HC Wainwright Issues Negative Outlook for Ardelyx Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at HC Wainwright dropped their Q1 2025 EPS estimates for Ardelyx in a note issued to investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Neutral” rating and a $5.50 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.

ARDX has been the topic of a number of other research reports. Citigroup reduced their price objective on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. StockNews.com upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Ardelyx in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.42.

Ardelyx Stock Up 4.7 %

Shares of Ardelyx stock opened at $4.71 on Wednesday. Ardelyx has a twelve month low of $3.83 and a twelve month high of $10.13. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -15.70 and a beta of 0.92. The company has a current ratio of 4.03, a quick ratio of 3.87 and a debt-to-equity ratio of 0.64. The company has a fifty day moving average price of $5.97 and a 200 day moving average price of $6.27.

Institutional Investors Weigh In On Ardelyx

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its holdings in Ardelyx by 1,026.3% in the second quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 3,233 shares during the last quarter. Redwood Wealth Management Group LLC acquired a new stake in shares of Ardelyx during the 2nd quarter worth approximately $62,000. Coastal Bridge Advisors LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth approximately $74,000. Helen Stephens Group LLC bought a new stake in shares of Ardelyx in the 3rd quarter worth approximately $76,000. Finally, Paloma Partners Management Co acquired a new position in Ardelyx during the 1st quarter valued at approximately $86,000. Institutional investors own 58.92% of the company’s stock.

Insider Activity at Ardelyx

In other news, CEO Michael Raab sold 32,225 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total value of $188,838.50. Following the completion of the sale, the chief executive officer now directly owns 1,227,009 shares in the company, valued at approximately $7,190,272.74. The trade was a 2.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Justin A. Renz sold 5,289 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total value of $30,993.54. Following the transaction, the chief financial officer now owns 295,257 shares in the company, valued at $1,730,206.02. This trade represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 247,983 shares of company stock valued at $1,514,002 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.